These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

91 related items for PubMed ID: 22723600

  • 1. Replication capacity of minority variants in viral populations can affect the assessment of resistance in HCV chimeric replicon phenotyping assays.
    Verbinnen T, Jacobs T, Vijgen L, Ceulemans H, Neyts J, Fanning G, Lenz O.
    J Antimicrob Chemother; 2012 Oct; 67(10):2327-37. PubMed ID: 22723600
    [Abstract] [Full Text] [Related]

  • 2. Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences from HCV clinical isolates.
    Sheaffer AK, Lee MS, Hernandez D, Chaniewski S, Yu F, Falk P, Friborg J, Zhai G, McPhee F.
    Antivir Ther; 2011 Oct; 16(5):705-18. PubMed ID: 21817192
    [Abstract] [Full Text] [Related]

  • 3. Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates.
    Qi X, Bae A, Liu S, Yang H, Sun SC, Harris J, Delaney W, Miller M, Mo H.
    Antiviral Res; 2009 Feb; 81(2):166-73. PubMed ID: 19063924
    [Abstract] [Full Text] [Related]

  • 4. A cellular replicon-based phenotyping assay to determine susceptibility of hepatitis C virus clinical isolates to NS3/4A protease inhibitors.
    Vijgen L, Verbeeck J, Van Kerckhove B, Berke JM, Koletzki D, Fanning G, Lenz O.
    Methods Mol Biol; 2013 Feb; 1030():105-17. PubMed ID: 23821263
    [Abstract] [Full Text] [Related]

  • 5. Development of hepatitis C virus chimeric replicons for identifying broad spectrum NS3 protease inhibitors.
    Binder J, Tetangco S, Weinshank M, Maegley K, Lingardo L, Diehl W, Love R, Patick AK, Smith GJ.
    Antiviral Res; 2011 Aug; 91(2):102-11. PubMed ID: 21620899
    [Abstract] [Full Text] [Related]

  • 6. Hepatitis C virus resistance to protease inhibitors.
    Halfon P, Locarnini S.
    J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
    [Abstract] [Full Text] [Related]

  • 7. Generation of a chimeric hepatitis C replicon encoding a genotype-6a NS3 protease and assessment of boceprevir (SCH503034) sensitivity and drug-associated mutations.
    Aloia AL, Eyre NS, Black S, Bent SJ, Gaeguta A, Guo Z, Narayana SK, Chase R, Locarnini S, Carr JM, Howe JA, Beard MR.
    Antivir Ther; 2015 Jul; 20(3):271-80. PubMed ID: 25222708
    [Abstract] [Full Text] [Related]

  • 8. Development and characterization of a replicon-based phenotypic assay for assessing HCV NS4B from clinical isolates.
    Rajyaguru S, Yang H, Martin R, Miller MD, Mo H.
    Antiviral Res; 2013 Nov; 100(2):328-36. PubMed ID: 24013002
    [Abstract] [Full Text] [Related]

  • 9. In Vitro Activity of Simeprevir against Hepatitis C Virus Genotype 1 Clinical Isolates and Its Correlation with NS3 Sequence and Site-Directed Mutants.
    Verbinnen T, Fevery B, Vijgen L, Jacobs T, De Meyer S, Lenz O.
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7548-57. PubMed ID: 26392483
    [Abstract] [Full Text] [Related]

  • 10. Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
    He Y, King MS, Kempf DJ, Lu L, Lim HB, Krishnan P, Kati W, Middleton T, Molla A.
    Antimicrob Agents Chemother; 2008 Mar; 52(3):1101-10. PubMed ID: 18086851
    [Abstract] [Full Text] [Related]

  • 11. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.
    Tong X, Chase R, Skelton A, Chen T, Wright-Minogue J, Malcolm BA.
    Antiviral Res; 2006 Jun; 70(2):28-38. PubMed ID: 16448708
    [Abstract] [Full Text] [Related]

  • 12. Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells.
    Lin K, Kwong AD, Lin C.
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4784-92. PubMed ID: 15561857
    [Abstract] [Full Text] [Related]

  • 13. Establishment of a robust hepatitis C virus replicon cell line over-expressing P-glycoprotein that facilitates analysis of P-gp drug transporter effects on inhibitor antiviral activity.
    Hernandez D, Falk P, Yu F, Zhai G, Quan Y, Faria T, Cao K, Scola P, McPhee F.
    Biochem Pharmacol; 2013 Jan 01; 85(1):21-8. PubMed ID: 23063413
    [Abstract] [Full Text] [Related]

  • 14. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
    Halfon P, Sarrazin C.
    Liver Int; 2012 Feb 01; 32 Suppl 1():79-87. PubMed ID: 22212577
    [Abstract] [Full Text] [Related]

  • 15. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
    Dahl G, Sandström A, Akerblom E, Danielson UH.
    Antivir Ther; 2007 Feb 01; 12(5):733-40. PubMed ID: 17713156
    [Abstract] [Full Text] [Related]

  • 16. Natural prevalence of HCV minority variants that are highly resistant to NS3/4A protease inhibitors.
    Franco S, Bellido R, Aparicio E, Cañete N, García-Retortillo M, Solà R, Tural C, Clotet B, Paredes R, Martínez MA.
    J Viral Hepat; 2011 Oct 01; 18(10):e578-82. PubMed ID: 21914079
    [Abstract] [Full Text] [Related]

  • 17. Two years' persistence of naturally present substitution R155K within hepatitis C virus NS3 protease in the absence of protease inhibitor-based therapy.
    Colson P, Gérolami R.
    J Infect Dis; 2011 May 01; 203(9):1341-2; author reply 1342-3. PubMed ID: 21459820
    [No Abstract] [Full Text] [Related]

  • 18. Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy.
    Vicenti I, Rosi A, Saladini F, Meini G, Pippi F, Rossetti B, Sidella L, Di Giambenedetto S, Almi P, De Luca A, Caudai C, Zazzi M.
    J Antimicrob Chemother; 2012 Apr 01; 67(4):984-7. PubMed ID: 22258932
    [Abstract] [Full Text] [Related]

  • 19. [Replication of the subgenomic hepatitis C virus replicon in the presence of the NS3 protease inhibitors: a stochastic model].
    Ivanisenko NV, Mishchenko EL, Akberdin IR, Demenkov PS, Likhoshvai VA, Kozlov KN, Todorov DI, Samsonova MG, Samsonov AM, Kolchanov NA, Ivanisenko VA.
    Biofizika; 2013 Apr 01; 58(5):758-74. PubMed ID: 25481944
    [Abstract] [Full Text] [Related]

  • 20. Inhibitory effects of Pycnogenol® on hepatitis C virus replication.
    Ezzikouri S, Nishimura T, Kohara M, Benjelloun S, Kino Y, Inoue K, Matsumori A, Tsukiyama-Kohara K.
    Antiviral Res; 2015 Jan 01; 113():93-102. PubMed ID: 25446333
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.